Registry of Castor and Cratos stent grafts for diseases of the chest aorta
Follows how Castor and Cratos stent grafts perform in people with chest aorta disease.
Key facts
- Who runs it
- Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd
- Where
- Sion and Zurich, SwitzerlandSee the 2 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 12 Sept 2025
- Expected to end
- Dec 2033
- Type of study
- Observational, 2 groups
- Treatments tested
- Implantation with Castor™ stent graft
- Implantation with Cratos™ stent graft
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a Castor™ or Cratos™ single branch stent graft placed in the main chest artery (aorta). The branch must go into the left subclavian artery, an artery to the left arm.
- Age
- Older than 18 years
- Sex
- All sexes
- Disease stage
- Disease of the thoracic aorta (the main artery in the chest) involving the aortic arch, such as a tear (dissection), a bulge (aneurysm), ulcers or bleeding in the artery wall.
- Earlier treatment
- People must have had a Castor™ or Cratos™ single branch stent graft placed, with a branch into the left subclavian artery (LSA).
Main reasons for not taking part
- Allergy to the materials of the device
- Severe infection, or infection that may spread through the body and raise the chance of the graft getting infected
- Minors and pregnant women
- A branch into a vessel other than the LSA
- Refusing to take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Implantation of a Castor™ or Cratos™ single branch endoprothesis with incorporation of the left subclavian artery
- Age >18 years
Who cannot take part
- Patients allergic to the materials of the device
- Patients with severe or potentially systemic infections that increase the chance of graft infection
- Minors and pregnant women
- Branch for other supra-aortic vessels than the LSA
- Rejection of participation
Where in Switzerland
Also in 1 other country, 2 sites
- Hôpital de SionSion, SwitzerlandContact: Daniel DanzerTaking people
- Universitätsspital Zürich USZZurich, SwitzerlandContact: Susanne MenzTaking people
About the trial
What the trial wants to find out
The Castor™ and Cratos™ Branched Aortic Stent Graft Systems are medical devices designed for the minimally invasive endovascular treatment of thoracic aortic pathologies in the descending aorta. The goal of this multi-centre retrospective and prospective observational registry study is to capture the short-, medium- to long-term safety and performance data of how Castor™ and Cratos™ stent-grafts work in real-world settings (everyday medical practice). The aim is to study approximately 100 patients in European hospitals, with competitive enrollment.
The 2 groups in the trial
- Cohort 1: patients treated with Castor™
Arch involving aortic pathologies treated with the Castor™ stent graft system.
Treatment: Implantation with Castor™ stent graft
- Cohort 2: patients treated with Cratos™
Arch involving aortic pathologies treated with the Cratos™ stent graft system.
Treatment: Implantation with Cratos™ stent graft
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- European Multi-Centre Castor™ and Cratos™ Branched Endovascular Arch Repair Registry
- Plain-language title
- Registry of Castor and Cratos stent grafts for diseases of the chest aortaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 25 June 2026